Phaseline

Targets › TSLP

TSLP (Thymic stromal lymphopoietin): drug programs, companies and trials

5 programs from 5 companies in 34 trials: 13 Phase 3, 13 Phase 2, 7 Phase 1, 1 Phase 4; Respiratory, Other, Oncology; next expected readout Dec 2026.

[Isoform 1]: Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells..; FUNCTION: [Isoform 2]: May act as an antimicrobial peptide in the oral cavity and on the skin. (UniProt, Q969D9)

Open in Phaseline: the race on TSLP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQC2731 injection
anti-TSLP monoclonal antibody; blocks TSLP signaling pathway and inhibits downstream cytok
TSLPPhase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Asthma; Chronic Obstructive Pulmonary DiseaseDec 2026
Suzhou Suncadia BiopharmaceuticalsSHR-8068 Injection
TSLP receptor antagonist
TSLPPhase 3Advanced Biliary Tract Cancer; Advanced Hepatocellular Carcinoma; Advanced or Metastatic Non-small Cell Lung Cancer; Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma …Dec 2026
AstraZenecaTezepelumab
Thymic stromal lymphopoietin inhibitor
TSLPPhase 3Chronic Rhinosinusitis With Nasal Polyps; Eosinophilic Esophagitis; Severe Asthma; Asthma …Jan 2027
Windward BioWIN378
TSLP ligand-blocking monoclonal antibody
TSLPPhase 2COPD (Chronic Obstructive Pulmonary Disease); AsthmaDec 2027
Shanghai Huaota BiopharmaceuticalHB0056
Bispecific antibody targeting TSLP and IL-11
TSLP, IL11Phase 1Healthy; AsthmaAug 2027

Conditions

Asthma (4) Severe Asthma (3) Chronic Rhinosinusitis With Nasal Polyps (2) Chronic Obstructive Pulmonary Disease (COPD) (2) Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (1) Chronic Obstructive Pulmonary Disease (1) Advanced Biliary Tract Cancer (1) Advanced Hepatocellular Carcinoma (1) Advanced or Metastatic Non-small Cell Lung Cancer (1) Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma (1) Biliary Tract Cancer (1) Gastric Cancer (1)

Modalities

small molecule (3), mixed (1), antibody (1)

Companies

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Suzhou Suncadia Biopharmaceuticals (1) AstraZeneca (1) Shanghai Huaota Biopharmaceutical (1) Windward Bio (1)

Related targets

IL11 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.